AbbVie
Biotech

AbbVie pens $1.4B deal for deprioritized IBD drug from Nxera

AbbVie has added another angle to its relationship with Nxera, paying $100 million upfront for a phase 1 inflammatory bowel disease candidate.
James Waldron Nov 4, 2026 7:20am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
a lot of scissors

Ultragenyx shrinks workforce and axes assets to halve R&D spend

Nov 4, 2026 5:19am
Sanofi headquarters Sanofi

Sanofi scraps Nurix program 2 months after entering clinic

Nov 4, 2026 5:02am
Doustdar

Novo aims for deals to ‘close some gaps’ as misfires hit profits

Nov 4, 2026 4:01am
AbbVie Oxford

AbbVie invests £120M in UK, including new R&D headquarters

Nov 4, 2026 2:31am
More News

Rhythm drums up LG obesity license to as much as $855M

Nov 3, 2026 9:32am

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

Nov 3, 2026 8:38am

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am